PET117 cytochrome c oxidase chaperoneGenealiases: CSRP2BP · MC4DN19
Q-omics provides the consensus-scored PET117 profile across patient tissues and cancer cell-line models. PET117 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PET117 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, PET117 RNA expression shows 18,286 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, HNSC, and UVM as cancer lineages where PET117 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PET117 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PET117 survival associations across molecular data types. PET117 RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PET117 RNA expression–survival associations across cancer types. High PET117 expression shows unfavorable associations in LIHC, KICH, LUSC, PCPG and COAD, but favorable associations in KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PET117 RNA expression.
This table summarizes PET117 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PET117. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PET117 shows higher tumor expression in HNSC, LIHC, BLCA, BRCA, CHOL and LUSC. The HNSC box plot shows higher PET117 RNA expression in tumor versus normal tissue (log2 FC = +0.747, t-test p < 0.001).
This table shows molecular features associated with PET117 in patient tissues and cancer cell lines. In patient samples, PET117 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PET117 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
